Stealth Biotherapeutics
123 Highland Ave, Suite 201
Needham
Massachusetts
02494
United States
Tel: (617) 600-6888
Website: http://www.stealthbt.com/
150 articles about Stealth Biotherapeutics
-
Reenie McCarthy, chief executive officer of Stealth Biotherapeutics, has seen first-hand the negative impact of mitochondrial diseases, including watching an athlete decline from being an Olympic-level rower to becoming wheelchair-bound.
-
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
10/10/2019
Elamipretide in Phase 3 development for primary mitochondrial myopathy If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license
-
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
10/7/2019
Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the presentation of pre-clinical data for its lead pipeline compound, SBT-272, at the 18th Annual Northeast Amyotrophic Lateral Sclerosis Consortium in Clearwater Beach, Fla.
-
Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference
10/1/2019
Stealth BioTherapeutics Corp announced that Reenie McCarthy, Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 5:20 p.m. ET in New York.
-
Stealth BioTherapeutics to Attend Upcoming Investor Conferences
9/20/2019
Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that management will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24th, 2019 in New York.
-
Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer
9/3/2019
Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the appointment of Robert Weiskopf as Chief Financial Officer (CFO).
-
Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights
8/14/2019
Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the three and six months ended June 30, 2019 and provided a corporate update, including the announcement of a new Board member, Dr. Louis G. Lange.
-
Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders
7/2/2019
Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the Company will host a key opinion leader (KOL) breakfast symposium on Thursday, July 11, 2019 at 8:00 a.m. ET in New York City.
-
Stealth Biotherapeutics to Present at Upcoming Investor Conferences
5/30/2019
Stealth BioTherapeutics Corp. announced that Reenie McCarthy, CEO, will present at two investor conferences in Jun:
-
Stealth BioTherapeutics Reports First Quarter 2019 Financial Results And Recent Business Highlights
5/15/2019
Stealth BioTherapeutics Corp. reported financial results for the quarter ended March 31, 2019.
-
Stealth BioTherapeutics to Present at UBS Global Healthcare Conference
5/14/2019
Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the UBS Global Healthcare Conference in New York on Tuesday, May 21st 2019, at 2:30pm ET.
-
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Ophthalmic Conditions
4/30/2019
Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, recently presented positive results from its ophthalmic programs in dry age-related macular degeneration (AMD) and Leber's hereditary optic neuropathy (LHON).
-
Stealth BioTherapeutics Completes Enrollment of Pivotal Study in Primary Mitochondrial Myopathy
4/25/2019
Stealth BioTherapeutics announced completion of enrollment for MMPOWER-3, with top-line data expected by year end.
-
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
4/16/2019
Design and results from TAZPOWER and the TAZPOWER open-label extension were presented as late-breaking abstracts at the 2019 MDA Clinical & Scientific Conference
-
Stealth BioTherapeutics Reports Fiscal Year 2018 Financial Results and Recent Business Highlights
4/5/2019
FDA interactions on Barth syndrome and Leber's hereditary optic neuropathy expected by mid-year
-
Stealth BioTherapeutics Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide For The Treatment Of Dry AMD
3/28/2019
Study will assess safety, efficacy and pharmacokinetics of subcutaneous injections of elamipretide in adults with dry AMD with geographic atrophy
-
Stealth BioTherapeutics Announces Partial Exercise and Closing of Over-Allotment Option
3/4/2019
Stealth BioTherapeutics announced that it has issued an additional 588,232 American Depositary Shares at the public offering price of $12.00 per ADS, resulting in additional gross proceeds of approximately $7.1 million, pursuant to the exercise in part of the underwriters' over-allotment option in connection with Stealth's previously announced initial public offering of ADSs.
-
Stealth BioTherapeutics Announces Pricing of Initial Public Offering
2/15/2019
Stealth BioTherapeutics announced the pricing of its initial public offering of 6,500,000 American Depositary Shares, each representing 12 ordinary shares of Stealth, at an initial public offering price of $12.00 per ADS.
-
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
-
Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Dry Age-Related Macular Degeneration with Geographic Atrophy
12/10/2018
Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead investigational candidate, elamipretide,